Results 101 to 110 of about 2,602 (175)
Inter and intrapatient evolution of hepatitis C virus [PDF]
, 2015 Hepatitis C virus (HCV) has a short replication time, high mutation rates and large population sizes, all of which make it an excellent experimental model for evolution studies, because evolution can be visualized in real-time. In this review, we discuss
Campos, Rodolfo Hector +2 more
core +1 more source
Modulation of chimeric antigen receptor surface expression by a small molecule switch
BMC Biotechnology, 2019 Background Engineered therapeutic cells have attracted a great deal of interest due to their potential applications in treating a wide range of diseases, including cancer and autoimmunity.
Alexandre Juillerat +8 more
doaj +1 more source
Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro : a different effect on asunaprevir versus daclatasvir and beclabuvir [PDF]
, 2019 Direct-acting antivirals, asunaprevir (ASV), daclatasvir (DCV), and beclabuvir (BCV) are known to be mainly metabolized by CYP3A enzymes; however, the differences in the detailed metabolic activities of CYP3A4 and CYP3A5 on these drugs are not well ...
Ariyoshi, Noritaka +12 more
core +1 more source
Direct-acting antiviral therapy in patients with HCV hepatitis and severe fibrosis or cirrhosis [PDF]
, 2016 Introduzione: l’epatite cronica C è la più comune infezione virale trasmessa per via ematica e la principale causa di mortalità tra le epatopatie. La terapia antivirale può prevenire la progressione della malattia nei pazienti HCV.
Vitale, Giovanni <1980>
core +1 more source
The Scientific World Journal, 2013 Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (
Hee Bok Chae +2 more
doaj +1 more source
PLoS ONE, 2017 The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients. However, the risk in patients treated with interferon-free direct-acting antivirals (DAAs) is unknown. We
Yuko Nagaoki +23 more
doaj +1 more source
Kaohsiung Journal of Medical Sciences, 2017 Direct-acting antiviral agents (DAAs) have been widely used for chronic hepatitis C (CHC) treatment recently. The characteristics of glucose abnormalities after DAAs therapy however, remain elusive.
Jee-Fu Huang +12 more
doaj +1 more source
History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C [PDF]
, 2015 The development of antiviral drugs is a very complex process. Currently, around 50 drugs have been approved for human use against viruses such as HSV, HIV-1, the cytomegalo virus, the influenza virus, HBV and HCV.
Barrera Saldaña, Hugo Alberto +5 more
core
Programmable protein circuits in living cells [PDF]
, 2018 Synthetic protein-level circuits could enable engineering of powerful new cellular behaviors. Rational protein circuit design would be facilitated by a composable protein-protein regulation system in which individual protein components can regulate one ...
Chong, Lucy S. +3 more
core